Progression Clinical Trials

8 recruiting

Progression Trials at a Glance

50 actively recruiting trials for progression are listed on ClinicalTrialsFinder across 6 cities in 36 countries. The largest study group is Not Applicable with 17 trials, with the heaviest enrollment activity in Beijing, Paris, and Guangzhou. Lead sponsors running progression studies include SightGlass Vision, Inc., Shanghai Zhongshan Hospital, and IRCCS San Raffaele.

Browse progression trials by phase

Treatments under study

About Progression Clinical Trials

Looking for clinical trials for Progression? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Progression trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Progression clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 50 trials

Recruiting
Not Applicable

Children's Viewing Behavior

MyopiaMyopia ProgressionJuvenile Myopia
SightGlass Vision, Inc.20 enrolled1 locationNCT07229365
Recruiting
Not Applicable

Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses

MyopiaMyopia ProgressionJuvenile Myopia
SightGlass Vision, Inc.20 enrolled1 locationNCT07229352
Recruiting
Not Applicable

Evaluation of the Effectiveness of a New Generation of Myopia Control Lens on the Progression of Myopia in Children Aged 6 to 14 Years

Myopia Progression
Essilor International76 enrolled1 locationNCT07462897
Recruiting
Phase 3

The Effect of Myopia-Control Contact Lenses in New Zealand Chinese Children

Myopia Progression
Aston University66 enrolled1 locationNCT07535749
Recruiting
Not Applicable

Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression

Quality of LifeOligometastatic DiseaseToxicity Due to Radiotherapy+1 more
Robert Olson598 enrolled13 locationsNCT05784428
Recruiting

Domestic Environmental Exposure and Progression of ILD: An Exploratory Case-Control Study

Assess PID Diagnosis Revision After CMEI AuditAssess CMEI Recommendations' Impact on Respiratory HealthILD Progression and Exposure to Indoor Environnemental Risk+1 more
Ville de Paris100 enrolled2 locationsNCT07457502
Recruiting

Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer

Bladder CancerBladder Cancer RecurrenceAdjuvant Therapy for Bladder Cancer+1 more
Zhilong Dong400 enrolled1 locationNCT07424560
Recruiting
Phase 3

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

First Progression of Glioblastoma
European Organisation for Research and Treatment of Cancer - EORTC411 enrolled43 locationsNCT05904119
Recruiting
Not Applicable

Effect of MiYOSMART iQ Spectacle Lenses on Myopia Progression in Children

Myopia, Child Myopia Progression
Hoya Lens Rus LLC70 enrolled1 locationNCT07387159
Recruiting
Not Applicable

Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.

Brain MetastasisOligoprogression
Centre Francois Baclesse504 enrolled15 locationsNCT05102747
Recruiting

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

Multiple MyelomaSmoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)+2 more
Wake Forest University Health Sciences1,665 enrolled1 locationNCT06644625
Recruiting
Phase 3

Atropine in the Treatment of Myopia Study in Malaysia

Myopia Progression
IDB VisionCare SDN BHD144 enrolled2 locationsNCT07329777
Recruiting

Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization

Coronary Artery Bypass GraftingCoronary Artery Disease ProgressionCoronary Stenosis+1 more
Seung-Jung Park200 enrolled1 locationNCT03788369
Recruiting
Not Applicable

Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens

MyopiaMyopia ProgressionJuvenile Myopia
SightGlass Vision, Inc.150 enrolled14 locationsNCT06034327
Recruiting
Not Applicable

Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers

Oligometastatic DiseaseOligoProgressive Metastatic DiseaseOligoprogression
British Columbia Cancer Agency194 enrolled1 locationNCT06918951
Recruiting
Phase 2

Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

Metastatic Renal Cell CarcinomaRenal Cell CarcinomaOligoprogressive+1 more
Yale University30 enrolled1 locationNCT04974671
Recruiting
Not Applicable

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory+2 more
University Health Network, Toronto144 enrolled1 locationNCT06485076
Recruiting
Phase 1

Radiologic Pathologic Correlation of Imaging to Distinguish True Progression From Pseudoprogression in Brain Malignancies

Brain MalignanciesPseudoprogression
M.D. Anderson Cancer Center25 enrolled1 locationNCT06199479
Recruiting

Clinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study

Coronary Artery DiseaseCoronary Artery Disease Progression
Peking Union Medical College Hospital120 enrolled1 locationNCT06845410
Recruiting

Plaque Reversal With Early, Aggressive Lipid Lowering Therapy

Coronary Artery Disease Progression
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)60 enrolled1 locationNCT05783804